EUCTR2004-004686-15-DE进行中（未招募）不适用
Phase I/II study of immunization with multiple peptides mixed with the immunological adjuvant CpG 7909 in HLA-A2 patients with metastatic melanoma LUD 03-007 - LUD 03-007
udwig Institute For Cancer Research0 个研究点目标入组 14 人开始时间: 2005年1月18日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 14
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •standard inclusion criteria, see protocoll
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •standard exclusion criteria, see protocoll
研究者
相似试验
进行中（未招募）
不适用
Phase I/II Studie zur Immunisierung mit dem Peptid MAGE-3.A1 gemischt mit der immunologischen Adjuvans CpG 7909 bei Patienten mit metastasiertem Melanom - LUD 02-001Phase I/II Studie zur Immunisierung mit dem MAGE-3.A1 Peptid gemischt mit der immunologischen Adjuvans CpG 7909 für Patienten mit metastastasiertem MelanomEUCTR2004-004684-30-DEudwig Institute for Cancer Research14
已完成
2 期
Phase II study of Vaccination with Epitope peptides in combiNation with gemcitabine for UnreSectable Pancreatic Cancernresectable Pancreatic CancerJPRN-UMIN000008082Yamaguchi University Hospital60
招募中
1 期
Phase I study of Multiple-Vaccine Therapy in Patient with Refractory Breast Cancer to Chemotherapy.Breast CancerJPRN-UMIN000002408Department of Breast and Endocrine Surgery, Juntendo University School of Medicine6
已完成
1 期
Phase I study of Multiple-Vaccine Therapy in Patient with Refractory Non-Small-Cell Lung Cancer to Chemotherapy.on-Small-Cell Lung CancerJPRN-UMIN000002141Department of Respiratory Medicine, Juntendo University School of Medicine9
进行中（未招募）
1 期
Anti-tumoral vaccination of melanoma patients with peptides associated with GM-CT-01, a vegetal derived sugar that binds to and blocks galectin, a protein produced by tumor cells that inhibits immune cells.Metastatic melanomaMedDRA version: 14.0Level: LLTClassification code 10025651Term: Malignant melanoma excisionSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 14.0Level: LLTClassification code 10027150Term: Melanoma malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10042550Term: Superficial spreading melanoma stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10029488Term: Nodular melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10025662Term: Malignant melanoma of skin of scalp and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10040891Term: Skin melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10056768Term: Malignant melanoma of skin of lower limb, incl hipSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10048434Term: Melanoma malignant aggravatedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10042548Term: Superficial spreading melanoma in situSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10025652Term: Malignant melanoma in situSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-018638-29-BECentre du Cancer des Cliniques Universitaires Saint-Luc6